You can buy Capmaxen at the lowest price at Nextgen.ooo online pharmacy. Capmatinib is a small molecule kinase inhibitor that targets c-Met (also known as hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that activates signaling cascades involved in organ regeneration and tissue repair in healthy individuals. Aberrant activation of c-Met through mutations, amplification, and/or overexpression is known to occur in many types of cancer and leads to overactivation of several downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in MET have been detected in non-small cell lung cancer (NSCLC), and the prevalence of MET amplification in epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI)-naïve NSCLC patients is 1.4% to 21%. This combination has made c-Met a desirable target for the treatment of NSCLC.
 
Capmatinib received accelerated approval from the FDA on May 6, 2020, for the treatment of NSCLC in patients whose tumors harbor a MET exon 14 skipping mutation. Capmatinib inhibits the phosphorylation of both wild-type and mutant c-Met variants triggered by binding of its endogenous ligand, hepatocyte growth factor, while preventing c-Met-mediated phosphorylation of downstream signaling proteins and the proliferation and survival of c-Met-dependent tumor cells.